Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45 results about "Cholinergic system" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cholinergic system. Definition. A system of nerve cells that uses acetylcholine in transmitting nerve impulses. Supplement. The cholinergic system is a neurotransmitter system involved in the regulation of memory and learning. It is this system that degenerates in Alzheimer's disease.
Azabicyclic compounds are central nervous system active agents
Compounds of formula (I)are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.
Owner:ABBVIE INC
Method of evaluating suitability for drug therapy for the prevention and treatment of anxiety disorders using cholinergic type ii theta rhythm
InactiveUS20120143074A1Effective treatmentSuitable for useElectroencephalographyCompounds screening/testingMedicineRecurrent anxiety
The present invention relates to a drug suitability assessment method for the prevention or treatment of anxiety disorders using the cholinergic type II theta rhythm, and, more specifically, to a method for detecting individuals suffering from anxiety disorders induced by an abnormality occurring in the cholinergic system using the type II theta rhythm profile which is based on findings that the cholinergic type II theta rhythm is lower in an animal anxiety model than in normal subjects and that cholinergic drug treatment induces the cholinergic type II theta rhythm to return to normal and reduces anxiety and thereby making it possible to determine if a subject can be appropriately administered with a cholinergic drug and to monitor progress after cholinergic drug treatment.
Owner:KOREA INST OF SCI & TECH
Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
This invention relates to oxadiazolyl and thiadiazolyl derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Owner:NEUROSEARCH AS
Heteroaryl diazacycloalkanes, their preparation and use
InactiveUS20020045618A1Decreased cholinergic functionUseful in treatmentBiocideNervous disorderSmooth muscleAcetyl choline receptor
The present invention relates to novel heteroaryl diazacycloalkane derivatives which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Owner:NEUROSEARCH AS
Novel muscarinic receptor antagonist and application thereof
The invention relates to a novel muscarinic receptor antagonist and application thereof, relating to the preparation of novel ether compound of 3-azabicyclo(3, 3,1) nonanol and an optical isomer and quaternary ammonium salt thereof, and application of the compounds as medicament. The compounds show high affinity; and can be used for treating diseases or disease symptoms concerning the cholinergic systems of the central nervous system (CNS), and the peripheral nervous system (PNS), smooth muscle contraction, internal secretion, neurodegeneration, inflammation, aches, withdrawal caused by the termination of abuse of chemicals, and the like.
Owner:HEBEI RUISHENG MEDICINE TECH
Novel quinuclidine derivatives and their use
This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Owner:NEUROSEARCH AS
Novel diazabicyclic biaryl derivatives
This invention relates to novel diazabicyclic biaryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Owner:NEUROSEARCH AS
Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations
The invention discloses application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis. Researches shows that homomangiferin can improve damaged learning and memory ability of APP (amyloid protein precursor) transgenic mice evidently, and can improve relatively-long-term memory in short-term memory of the APP transgenic mice. The homomangiferin can increase content of Ach (acetylcholine), improve activity of CHAT (choline acetyl transferase) and inhibit activity of AchE (acetylcholinesterase), and accordingly indexes in terms of APP transgenic dementia model pathology, cholinergic system, cell apoptosis and the like can be improved. The homomangiferin and homomangiferin compositions can be used for preparing pharmaceuticals for preventing senile dementia and hypomnesis.
Owner:KPC PHARM INC
Azabicyclic compounds are central nervous system active agents
Compounds of formula (I) are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.
Owner:DART MICHAEL J +3
Drug composition for enhancing memory of people rapidly exposed to high altitude, and preparation method thereof
The present invention discloses a drug composition for enhancing memory of people rapidly exposed to a high altitude. The drug composition comprises an active component and an auxiliary material, wherein the active component comprises taurine, ovolecithin, acetyl-L-carnitine, and huperzine a, and the auxiliary material comprises lactose, MCC and magnesium stearate, or comprises lactose and magnesium stearate. The drug composition has the following beneficial effects that: based on different mechanisms such as provision of essential nutrients for nerve cells, free radical removing, neurotransmitter acetylcholine precursor complementing, central cholinergic system regulation, and the like, a comprehensive effect is acted on human body, drug combination advantages are presented, and improvement of memory of people rapidly exposed to a high altitude is achieved.
Owner:URUMQI GENERAL HOSPITAL LANZHOU MILITARY AREA CHINESE P L A
Method for detecting zebrafish M3 receptor protein based on determination of p38MAPK protein expression
ActiveCN106053829AHigh sensitivityImprove stabilityBiological material analysisTesting waterPhosphorylationWater quality
A method for detecting zebrafish M3 receptor protein based on determination of p38MAPK protein expression comprises the following steps: (1), preparing a zebrafish brain tissue protein sample; (2), performing SDS (sodium dodecyl sulfate) gel electrophoresis; (3), performing film transferring; (4), closing; (5), performing primary and secondary antibody inoculation; (6), performing rendering reaction; (7), calculating M3 receptor variation results. The technical defect that traditional zebrafish M3 receptor detection is limited to zero specific antibody and accordingly is unable to use western immunoblotting is overcome, the use of p38MAPK phosphorylation level to determine changes in zebrafish M3 receptor protein content is provided for the first time, and the method is high in sensitivity, good in stability and free of complex equipment; meanwhile, the method is simple and quick to perform, high in specificity and low in cost; internal acting mechanism of a cholinergic system is studied in terms of molecules, and in connection with study on zebrafish behavior changes, finally water quality can be estimated and monitored online in real time.
Owner:SHANDONG NORMAL UNIV
Application of icaritin to medicine for treating Alzheimer disease
The invention relates to an application of icaritin to a medicine for treating the Alzheimer disease. Icaritin is taken as a main raw herb, and a proper amount of auxiliary materials are added to prepare an oral preparation or an injection. By deep and detailed research of icaritin on aspects, such as a pharmacological action and an action mechanism, it is found that icaritin can obviously reduce Abeta aggregation and cholinergic nerve functional impairment, due to Abeta<25-35>, of a dementia rat model, and obviously improves the learning and memory dysfunction of the dementia rat model. Icaritin can reduce Abeta aggregation and improves the function of brain cholinergic nerve, produces a function of resisting Abeta<25-35> neurotoxicity, and obviously improves the learning and memory ability of the dementia rat model. According to the invention, by researching the effects of icaritin on the learning and memory ability, the cholinergic system, and an Abeta metabolic pathway of the dementia rat model, the pharmacological action mechanism of icaritin on treating the Alzheimer disease is illustrated, and pharmacological foundations on application of further developing icaritin are provided.
Owner:ZUNYI NO 1 PEOPLES HOSPITAL
Medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease
InactiveCN108671207AGood medical effectNervous disorderLeech/worm material medical ingredientsDiseaseWestern blot
The invention provides medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease, and has the outstanding medical treatment effect. A mice is feed with a brain andheart beneficial tablet water solution, the brain and heart beneficial tablets are proved to have the efficacy of preventing and treating Alzheimer's disease through behavioral experiments (mine test,jump platform test, Y maze test and water maze test), immunohistochemical,serum and cortical brain ELISA measuring and western blot, forming of Abeta plaque in the brain can be reduced, and the pathologic condition of Alzheimer's disease can be improved by adjusting the oxidative stress and cholinergic system.
Owner:JILIN UNIV
Health care product composition capable of promoting cognition and memory abilities and preparation method thereof
ActiveCN108785333AEnhance memoryImprove cognitive abilityNervous disorderFungi medical ingredientsDiseaseSuperoxide dismutases
The invention provides a health care product composition capable of promoting cognition and memory abilities and a preparation method thereof. The health care product composition is mainly prepared from Hericium erinaceus, honey fungus and amanita caesarea fruiting body powder, the composition prepared from the mixed bacterial powder can promote the content of superoxide dismutase in the brain byan oxidative stress way, so as to help clear active oxygen in the organism, strengthen the function of the central cholinergic system, and finally promote the cognition and memory abilities, and relieve and treat the symptom of alzheimer disease.
Owner:JILIN UNIV
Method for determining zebrafish M receptor level based on bio-luminescence method
ActiveCN106047984AHigh sensitivityImprove stabilityMicrobiological testing/measurementChemiluminescene/bioluminescenceMechanism of actionWater quality
The invention discloses a method for determining a zebrafish M receptor level based on a bio-luminescence method. The method comprises the following steps: preparing a zebrafish tissue supernatant, and converting GDP and GMP into GTP; destroying ATP and UTP; converting the GTP into the ATP; and detecting the ATP and processing and computing data, so that change in the zebrafish M receptor level is obtained. The method disclosed by the invention, which is used for detecting the change in the content of a zebrafish M receptor based on the bio-luminescence method, is provided for the first time, and the method is unnecessary to determine the protein content of the M receptor; the method is high in sensitivity, good in stability and free from use of complex equipment; the method disclosed by the invention is simple and convenient to operate, high in specificity and low in cost; the internal operating mechanism of a cholinergic system is researched in molecular aspect, and researches on the change of zebrafish behaviors are conducted, so that real-time online assessment and monitoring on water quality are finally achieved.
Owner:SHANDONG NORMAL UNIV
Active substance combination for medicamentous therapy of habituation of or habitual material or narcotics
InactiveCN1527711AReduce alcohol consumptionNervous disorderAmide active ingredientsNarcoticBULK ACTIVE INGREDIENT
The invention relates to an active ingredient combination of at least one modulator of the cholinergic system and at least one substance with an anti-excitatory action for treating a dependence on addictive substances or narcotics, in particular for treating alcoholism.
Owner:HF ARZNEIMITTELFORSCHUNG
Application of dioscin to preparation of medicines for treating Alzheimer's diseases
InactiveCN110755444ASafePracticalOrganic active ingredientsNervous disorderNerve cellsOxidative injury
The invention discloses an application of dioscin to preparation of medicines for treating Alzheimer's diseases. The Morris water maze testing result shows that a dioscin administration group can shorten the escaping latency period, prolong original platform quadrant residence time and increase the number of times of passing through a platform, which indicates that the dioscin can significantly improve the spatial learning and memorizing capacity of AD mice; the gait analysis result indicates that the dioscin can significantly increase the gait indexes of the AD mice, and strengthen the physical strength of the AD mice, so that the movement velocity of the AD mice is accelerated, the stride frequency is increased, the stepping length is increased and the duty cycle can be significantly shortened; the dioscin can significantly reduce the MDA level in hippocampal tissue of the AD mice, increase the GSH level and the SOD level, and improve oxidative damage of brain tissue of the AD mice;and the dioscin can restrain AchE activity of the hippocampal tissue, increase ChAT level, influence a cholinergic system, obviously improve the pathology structure of the brain tissue of the AD miceand ultrastructural damage of nerve cells. The dioscin can be used as a single effective component to be prepared into medicines, and can be combined with other medicines for preparing a compound preparation.
Owner:DALIAN MEDICAL UNIVERSITY
Azaring-ether derivatives and their use as nicotinic ACh receptor modulators
The present invention relates to novel pyridylether derivatives which are cholinergic ligands at nicotinic Ach receptors. The compounds of the invention are useful for the treatment of conditions, disorders, or diseases involving the cholinergic system of the central nervous system, pain, inflammatory diseases, diseases caused by smooth muscle contractions and as assistance in the cessation of chemical substance abuse.
Owner:ANIONA APS
Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations
The invention discloses application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis. Researches shows that homomangiferin can improve damaged learning and memory ability of APP (amyloid protein precursor) transgenic mice evidently, and can improve relatively-long-term memory in short-term memory of the APP transgenic mice. The homomangiferin can increase content of Ach (acetylcholine), improve activity of CHAT (choline acetyl transferase) and inhibit activity of AchE (acetylcholinesterase), and accordingly indexes in terms of APP transgenic dementia model pathology, cholinergic system, cell apoptosis and the like can be improved. The homomangiferin and homomangiferin compositions can be used for preparing pharmaceuticals for preventing senile dementia and hypomnesis.
Owner:KPC PHARM INC
Application of flavonoid compound to preparation of cholinesterase inhibitor and medicine for preventing and/or treating Alzheimer disease
PendingCN113274383AHelp to combineStrong inhibitory activityOrganic active ingredientsNervous disorderDiseaseCholinesterase
The invention provides an application of a flavonoid compound to preparation of a cholinesterase inhibitor and a medicine for preventing and / or treating Alzheimer's disease, and belongs to the technical field of medicines. The invention provides the application of the flavonoid compound to preparation of the cholinesterase inhibitor. The flavonoid compound is specifically a compound Eriosematin. According to the invention, the compound Eriosematin has extremely efficient inhibition activity on cholinesterase, and can be used for preventing and / or treating Alzheimer's disease caused by cholinergic system damage.
Owner:QIQIHAR UNIVERSITY
n-oxides of diazabicyclononylpyrimidine derivatives and their medicinal uses
The present invention relates to novel N-oxides of certain diazabicyclononylpyrimidine derivatives and their use in the preparation of pharmaceutical compositions. The compounds of the present invention were found to be cholinergic ligands of nicotinic acetylcholine receptors and modulators of monoamine receptors and transporters. Due to their pharmacological properties, the compounds of the present invention can be used in the treatment of different diseases or disorders, for example diseases or disorders involving the cholinergic system of the central nervous system (CNS), peripheral nervous system (PNS), diseases involving smooth muscle contraction or disorder, endocrine disease or disorder, disease or disorder involving neurodegeneration, disease or disorder involving inflammation, pain, and withdrawal symptoms resulting from cessation of chemical substance abuse.
Owner:NEUROSEARCH AS
A pharmaceutical composition for enhancing the memory of people rapidly advancing to plateau and its preparation method
The invention discloses a pharmaceutical composition for enhancing the memory of people rapidly entering plateaus. The pharmaceutical composition is composed of active components and auxiliary materials; the active components are composed of taurine, egg yolk lecithin, acetyl-L-carnitine and huperzine A Composition; The excipients consist of lactose, MCC and magnesium stearate or consist of lactose and magnesium stearate. The beneficial effects of the present invention are as follows: the pharmaceutical composition provided by the present invention for enhancing the memory of people rapidly advancing to plateau provides essential nutrients for nerve cells, scavenging free radicals, supplementing neurotransmitter acetylcholine precursors, and regulating the functions of the central cholinergic system, etc. Starting from different mechanisms of action, they act comprehensively on the body, which embodies the advantages of combined medication and achieves the effect of improving the memory of people who are rapidly entering the plateau.
Owner:URUMQI GENERAL HOSPITAL LANZHOU MILITARY AREA CHINESE P L A
Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
This invention relates to novel 1,4-diaza-bicyclo [3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
![Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use](https://images-eureka.patsnap.com/patent_img/25f829d0-691b-4dc2-8acf-c7824c7fd153/DPA00001137510600011.png "Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use")
![Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use](https://images-eureka.patsnap.com/patent_img/25f829d0-691b-4dc2-8acf-c7824c7fd153/FPA00001137510700011.png "Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use")
![Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use](https://images-eureka.patsnap.com/patent_img/25f829d0-691b-4dc2-8acf-c7824c7fd153/GPA00001137510800021.png "Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use")
Owner:NEUROSEARCH AS
New use of donepezil hydrochloride in preparation of drugs for treating amyotrophic lateral sclerosis
InactiveCN105748475AReduced cholinergic functionIncrease concentrationNervous disorderHeterocyclic compound active ingredientsSynapseCholinergic cells
The invention discloses a new use of donepezil hydrochloride for preparing drugs for treating amyotrophic lateral sclerosis, and belongs to a cholinesterase inhibitor. The invention aims to study preparation of drugs for treating motor neuron disease. The new use is characterized in that patients orally take donepezil hydrochloride. Before motoneurons of the patients with amyotrophic lateral sclerosis are dead, the cholinergic functions are reduced, and terminally ill patients with amyotrophic lateral sclerosis have the cholinergic functions of brains and spinal cords further reduced along with motoneuron loss. Donepezil hydrochloride can inhibit hydrolytic action of postsynaptic membrane acetylcholinesterase on acetylcholine transmitter substances, increases the acetylcholine concentration so as to increase the cholinergic neuron conduction activity, and is an effective method for improving cholinergic system functions.
Owner:彭福华
Novel quinuclidine derivatives and their use
The present invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmaceutical properties, the compounds of the invention can be used in the treatment of diseases or conditions associated with the cholinergic system of the central nervous system (CNS), peripheral nervous system (PNS), diseases or conditions associated with smooth muscle contraction, endocrine diseases or conditions, diseases or conditions related to neurodegeneration, diseases or conditions related to inflammation, pain, and withdrawal symptoms from chemical substance abuse, among many others.
Owner:NEUROSEARCH AS
A method based on measuring p38mapk protein expression to detect zebrafish m3 receptor protein
ActiveCN106053829BHigh sensitivityImprove stabilityBiological material analysisTesting waterPhosphorylationWater quality
Owner:SHANDONG NORMAL UNIV
Novel 2,5-diazabicyclo [2.2.1] heptane derivatives
The present invention relates to novel 2,5-diazabicyclo[2.2.1]heptane derivatives, which are found to be potent modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
![Novel 2,5-diazabicyclo [2.2.1] heptane derivatives](https://images-eureka.patsnap.com/patent_img/519b88db-a57f-460b-af8c-3395d052298d/02805077.PNG "Novel 2,5-diazabicyclo [2.2.1] heptane derivatives")
![Novel 2,5-diazabicyclo [2.2.1] heptane derivatives](https://images-eureka.patsnap.com/patent_img/519b88db-a57f-460b-af8c-3395d052298d/C028050770002C1.PNG "Novel 2,5-diazabicyclo [2.2.1] heptane derivatives")
![Novel 2,5-diazabicyclo [2.2.1] heptane derivatives](https://images-eureka.patsnap.com/patent_img/519b88db-a57f-460b-af8c-3395d052298d/C0280507700081.PNG "Novel 2,5-diazabicyclo [2.2.1] heptane derivatives")
Owner:NEUROSEARCH AS
Pyridylether derivatives, their preparation and use
Owner:SANIONA AS
Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
![Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use](https://images-eureka.patsnap.com/patent_img/6388c29d-a080-4d13-aad6-583dcc3d1137/000001.png "Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use")
![Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use](https://images-eureka.patsnap.com/patent_img/6388c29d-a080-4d13-aad6-583dcc3d1137/000002.png "Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use")
![Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use](https://images-eureka.patsnap.com/patent_img/6388c29d-a080-4d13-aad6-583dcc3d1137/000003.png "Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use")
Owner:NEUROSEARCH AS
Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
This invention relates to novel triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Owner:NEUROSEARCH AS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com